Literature DB >> 28149633

Keap1/Nrf2 impairing revised: are we missing the single nucleotide polymorphisms?

Lucia Anna Muscarella1, Vito Michele Fazio2.   

Abstract

Entities:  

Year:  2016        PMID： 28149633      PMCID： PMC5227254          DOI： 10.21037/jtd.2016.12.85

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  17 in total

1.  KEAP1 Genetic Polymorphisms Associate with Breast Cancer Risk and Survival Outcomes.

Authors:  Jaana M Hartikainen; Maria Tengström; Robert Winqvist; Arja Jukkola-Vuorinen; Katri Pylkäs; Veli-Matti Kosma; Ylermi Soini; Arto Mannermaa
Journal:  Clin Cancer Res       Date:  2015-01-14       Impact factor: 12.531

2.  Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer.

Authors:  Lucia Anna Muscarella; Paola Parrella; Vito D'Alessandro; Annamaria la Torre; Raffaela Barbano; Andrea Fontana; Antonio Tancredi; Vito Guarnieri; Teresa Balsamo; Michelina Coco; Massimiliano Copetti; Fabio Pellegrini; Patrizia De Bonis; Michele Bisceglia; Gerardo Scaramuzzi; Evaristo Maiello; Vanna Maria Valori; Giuseppe Merla; Gianluigi Vendemiale; Vito Michele Fazio
Journal:  Epigenetics       Date:  2011-06-01       Impact factor: 4.528

Review 3.  Keap1: one stone kills three birds Nrf2, IKKβ and Bcl-2/Bcl-xL.

Authors:  Hui Tian; Baofu Zhang; JieHui Di; Guan Jiang; FeiFei Chen; HuiZhong Li; LianTao Li; DongSheng Pei; JunNian Zheng
Journal:  Cancer Lett       Date:  2012-06-26       Impact factor: 8.679

Review 4.  Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters.

Authors:  Xupeng Bai; Yibei Chen; Xiangyu Hou; Min Huang; Jing Jin
Journal:  Drug Metab Rev       Date:  2016-06-20       Impact factor: 4.518

5.  miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells.

Authors:  Gabriel Eades; Muhua Yang; Yuan Yao; Yongshu Zhang; Qun Zhou
Journal:  J Biol Chem       Date:  2011-09-16       Impact factor: 5.157

6.  Regulation of KEAP1 expression by promoter methylation in malignant gliomas and association with patient's outcome.

Authors:  Lucia Anna Muscarella; Raffaela Barbano; Vincenzo D'Angelo; Massimiliano Copetti; Michelina Coco; Teresa Balsamo; Annamaria la Torre; Angelo Notarangelo; Michele Troiano; Salvatore Parisi; Nadia Icolaro; Domenico Catapano; Vanna Maria Valori; Fabio Pellegrini; Giuseppe Merla; Massimo Carella; Vito Michele Fazio; Paola Parrella
Journal:  Epigenetics       Date:  2011-03-01       Impact factor: 4.528

Review 7.  Epigenetic regulation of Keap1-Nrf2 signaling.

Authors:  Yue Guo; Siwang Yu; Chengyue Zhang; Ah-Ng Tony Kong
Journal:  Free Radic Biol Med       Date:  2015-06-25       Impact factor: 7.376

Review 8.  NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer.

Authors:  John D Hayes; Michael McMahon
Journal:  Trends Biochem Sci       Date:  2009-03-25       Impact factor: 13.807

Review 9.  Role of the Keap1-Nrf2 pathway in cancer.

Authors:  Hanna M Leinonen; Emilia Kansanen; Petri Pölönen; Merja Heinäniemi; Anna-Liisa Levonen
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

10.  Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression.

Authors:  Richard Cowper-Sal lari; Xiaoyang Zhang; Jason B Wright; Swneke D Bailey; Michael D Cole; Jerome Eeckhoute; Jason H Moore; Mathieu Lupien
Journal:  Nat Genet       Date:  2012-09-23       Impact factor: 38.330
View more
  2 in total

1.  Prognosis of hormone-dependent breast cancer seems to be influenced by KEAP1, NRF2 and GSTM1 genetic polymorphisms.

Authors:  Micaela Almeida; Mafalda Soares; Ana Cristina Ramalhinho; José Fonseca Moutinho; Luiza Breitenfeld
Journal:  Mol Biol Rep       Date:  2019-04-02       Impact factor: 2.316

Review 2.  Epigenetic versus Genetic Deregulation of the KEAP1/NRF2 Axis in Solid Tumors: Focus on Methylation and Noncoding RNAs.

Authors:  F P Fabrizio; A Sparaneo; D Trombetta; L A Muscarella
Journal:  Oxid Med Cell Longev       Date:  2018-03-13       Impact factor: 6.543
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.